ANP32A and metastatic malignant neoplasm in the lymph nodes: Patients with a high level of ANP32A expression defined by Allred and IRS scoring systems were respectively found to have a 2.2-fold (95% CI, 1.2-4.0) and 2.0-fold (95% CI, 1.1-3.6) risk of contracting N2/N3 of lymph node metastasis.